Medication-assisted Treatment (MAT) Market Players:
- Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mallinckrodt Pharmaceuticals
- Titan Pharmaceuticals, Inc.
- Alkermes plc
- Orexo AB
- Mylan N.V.
- Teva Pharmaceuticals Industries Ltd.
- Lupin limited
- Hikma Pharmaceuticals PLC
- Novartis AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of medication-assisted treatment is estimated at USD 12.09 billion.
The global medication-assisted treatment market size crossed USD 11.2 billion in 2025 and is likely to register a CAGR of over 8.8%, exceeding USD 26.03 billion revenue by 2035.
By 2035, the North America region is projected to secure about 45% share in the medication-assisted Treatment Market, supported by intensified funding for MAT programs, expanded treatment capacity, and broader regulatory integration into mainstream healthcare owing to increased institutional backing.
Key players in the market include Indivior PLC, Mallinckrodt Pharmaceuticals, Titan Pharmaceuticals Inc., Alkermes plc, Orexo AB, Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Limited, Hikma Pharmaceuticals PLC, Novartis AG.
